Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-18
2006-07-18
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07078398
ABSTRACT:
The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefor. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially free of R-tofisopam with another anti-convulsant.
REFERENCES:
patent: 3736315 (1973-05-01), Kórösi et al.
patent: 4322346 (1982-03-01), Kórösi et al.
patent: 4423044 (1983-12-01), Kórösi et al.
patent: 4614740 (1986-09-01), Láng et al.
patent: 4835152 (1989-05-01), Kórösi et al.
patent: 5204343 (1993-04-01), Andrási et al.
patent: 5459137 (1995-10-01), Andrási et al.
patent: 5519019 (1996-05-01), Andrási et al.
patent: 5521174 (1996-05-01), Andrási et al.
patent: 5639751 (1997-06-01), Andrási et al.
patent: 5795886 (1998-08-01), Anderson et al.
patent: 5891871 (1999-04-01), Xia et al.
patent: 6017965 (2000-01-01), Mueller et al.
patent: 6051610 (2000-04-01), Mueller et al.
patent: 6071970 (2000-06-01), Mueller et al.
patent: 6075018 (2000-06-01), Vágó et al.
patent: 6080736 (2000-06-01), Landry et al.
patent: 6649607 (2003-11-01), Leventer et al.
patent: 2057504 (1992-06-01), None
patent: 2122 070 (1972-06-01), None
patent: 0 492 485 (1992-07-01), None
patent: 178516 (1981-09-01), None
patent: WO 91/17159 (1991-11-01), None
patent: WO 92/11262 (1992-07-01), None
patent: WO 95/01357 (1995-01-01), None
“Long Evan Rats”, downloaded Sep. 22, 2005 from www.criver.com/research—models—and—services/research—models/Long—Evans—Rat—cat05.pdf (date available).
“About Rats”, Synapse Web, downloaded Sep. 22, 2005 from http://synapses.mcg.edu/anatomy/animals/aboutrats.stm, “Last Updated Dec. 26, 2001”.
“Animal Models—Long Evans Outbred Rats”, downloaded Sep. 22, 2005 from http://taconic.com/anmodels/longev.htm, (date unavailable).
S. Almquist et al., “Direct and Indirect Approaches to Enantiomeric Separation of Benzodiazepines Using Micro Column Techniques,”J. Chromatography A, 679:139-146 (1994).
N. Bargmann-Leyder et al., “A Comparison of LC and SFC for Cellulose- and Amylose-Derived Chiral Stationary Phases,”Chirality, 7:311-325 (1995).
A. Bond and M. Lader, “A Comparison of the Psychotropic Profiles of Tofisopam and Diazepam,”Eur. J. Clin. Pharmacol., 22:137-142 (1982).
M. Briley et al., “Tofisopam Enhances the Anticonvulsant Activity of Diazepam Against Some, but Not All, Convulsive Agents,”British J. Pharm., 82:300P (1984).
G. De Sarro et al., “GYKI 52466 and Related 2,3-benzodiazepines as Anticonvulsant Agents in DBA/2 Mice,”Eur. J. Pharmacol., 294:411-422 (1995).
I. Fellegvári et al., “Separation of Conformational Diastereomers of 2,3-Benzodiazepines by HPLC,”ChromatographyinSymposia Biologica Hungarica, H. Kalász and L.S. Ettre, Eds., 193-203 (1987).
V. Filip et al., “A Double-Blind, Placebo-Controlled Study with Tofizopam in Anxiety Neurosis,”Agressologie, 22:27-30 (1981).
I. Fitos et al., “Separation of Enantiomers of Benzodiazepines on the Chiral-AGP Column,”J. Chromatography A, 709:265-273 (1995).
E. Fogassy et al., “Studies on the Properties and Structure of Optically Active 1-(3,4-Dimethoxyphenyl)-4-Methyl-5-Ethyl-7,8-Dimethoxyl-5H-2,3-Benzodiazepine (Tofizopam),” inBio-Organic Heterocycles, H.C. van der Plas, L. Ötvös, and M. Simonyi, Eds., 229-233 (1984).
H. Goldberg et al., “Comparative Efficacy of Tofisopam and Placebo,”Am. J. Psychiatry, 136:196-199 (1979).
K. Imre et al., “A Tofizopam (Grandaxin®) Farmakokinetikaja es Metabolizmusa,”Acta Pharmaceutica Hungarica, 63:83-90 (1993).
C. Ito, “Behavioral Pharmacological Study on the Structure Activity Relationship of Benzodiazepine Derivatives: with Particular Reference to the Activity of 2,3-Benzodiazapine,”J. Tokyo Med. College, 39:369-384 (1981).
J. Kanto et al., “Tofizopam: a Benzodiazepine Derivative without Sedative Effect,”Intl. J. Clin. Pharm. Ther. Tox., 20:309-312 (1982).
K. Maier et al., “The Effect of Tofisopam on Psychic Performance in Persons With More Than Average Anxiety: A Controlled Experimental Trial,”Current Therapeutic Research, 35(4):541-548 (1984).
“Tofisopam”, Martindale, Royal Pharmaceutical Society of Great Britain, p. 620, col. 1 (1993).
T. Mennini et al., “Brain Levels of Tofisopam in the Rat and Relationship with Benzodiazepine Receptors,”Arch. Pharmacol., 321:112-115 (1982).
J. Molcan et al., “Tofizopam in the Therapy of Anxious-Depressive Syndroms,”Agressologie, 22:23-24 (1981).
F. Pal, “A Grandazin® Gyógyszertechnológiája,”Acta Pharmaceutica Hungarica, 63:67-78 (1993).
Pakkanen et al., “Comparative Study of the Clinical Effects of Tofizopam, Nitrazepam and Placebo as Oral Premedication,”British J. Anaesthesia, 1009-1012 (1980).
S. Pellow and S. File, “The Effects of Tofisopam, a 3,4-Benzodiazepine, in Animal Models of Anxiety, Sedation, and Convulsions,”Drug Dev. Res., 7:61-73 (1986).
L. Petócz and I. Kosóczky, “The Main Pharmacological Characteristics of Grandaxin (Tofisopam, EGYT-341),”Ther. Hungarica, 23:134-138 (1975).
L. Petócz, “The Pharmacological Effects of Tofisopam (Grandaxin)®,”Acta Pharmaceutica Hungarica, 63:79-82 (1993).
V. Saano and A. Urtti, “Tofizopam Modulates the Affinity of Benzodiazepine Receptors in the Rat Brain,”Pharm. Biochem. Behavior, 17:367-369 (1982).
V. Saano, “Tofisopam Selectively Increases the Action of Anticonvulsants,”Med. Biol., 64:201-206 (1986).
V. Saano et al., Tofisopam Enhances the Action of Diazepam Against Tremor and Convulsions,Med. Biol., 61:49-53 (1983).
T. Seppälä et al., “Tofisopam, a Novel 3,4-Benzodiazepine: Multiple-Dose Effects on Psychomotor Skills and Memory. Comparison with Diazepam and Interactions with Ethanol,”Psychopharmacology, 69:209-218 (1980).
M. Simonyi and I. Fitos, “Stereoselective Binding of a 2,3-Benzodiazepine to Human Serum Albumin,”Biochemical Pharmacology, 32(12):1917-1920 (1993).
R. Sladkà et al., “A Placebo-controlled Clinical Trial With Tofizopam in the Treatment of Anxiety Neurosis,”Ther. Hungarica, 27:176-180 (1979).
J. Szegó et al., “Selected Passages From the Clinical-Pharmacological and Clinical Trials of Grandaxin®,”Acta Pharmaceutica Hungarica, 63:91-98 (1993).
G. Toth et al., “Racemate Splitting of (±)-5-ethyl-1-(3,4-dimethoxyphenyl)-6,7-dimethoxy-4- methyl-5H-2,3-benzodiazepine an Anomalous Chiroptic Behavior of Enantiomer (1),”J. Heterocyclic Chem., 20:709-713 (1983).
G. Várady et al., “The Clinical Evaluation of Grandaxin Used in the Treatment of Outpatients (A Multicentric Study),”Ther. Hungarica, 23:153-158 (1975).
J. Visy and M. Simonyi, “The Role of Configuration and Conformation in the Binding of 2,3-Benzodiazepines to Human Serum Albumin,”Chirality, 1:271-275 (1989).
F. Zsila et al., “Separation and Identification of Tofisopam and Steroisomers by Hyphenated HPLC-CD Technique,”J. Liq. Chrom.&Rel. Technol., 22:713-719 (1999).
Kucharik Robert F.
Leventer Steven M.
Drinker Biddle & Reath LLP
Henley III Raymond J.
Monaco Daniel A.
Vela Pharamaceuticals, Inc.
LandOfFree
Compositions and methods for treating or preventing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating or preventing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating or preventing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3535927